These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 38635586

  • 1. A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.
    Seeger N, Gutknecht S, Zschokke I, Fleischmann I, Roth N, Metzger J, Weber M, Breitenstein S, Grochola LF.
    JMIR Res Protoc; 2024 May 13; 13():e54042. PubMed ID: 38635586
    [Abstract] [Full Text] [Related]

  • 2. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF.
    JAMA Surg; 2019 Jun 01; 154(6):e190484. PubMed ID: 30942874
    [Abstract] [Full Text] [Related]

  • 3. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Stracquadanio G, Vrugt B, Flury R, Schraml P, Würl P, Müller TH, Knippschild U, Henne-Bruns D, Breitenstein S, Clavien PA, Graf R, Bond GL, Grochola LF.
    Clin Cancer Res; 2016 Dec 15; 22(24):6069-6077. PubMed ID: 27283965
    [Abstract] [Full Text] [Related]

  • 4. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.
    Gentiluomo M, Corradi C, Vanella G, Johansen AZ, Strobel O, Szentesi A, Milanetto AC, Hegyi P, Kupcinskas J, Tavano F, Neoptolemos JP, Bozzato D, Hackert T, Pezzilli R, Johansen JS, Costello E, Mohelnikova-Duchonova B, van Eijck CHJ, Talar-Wojnarowska R, Hansen CP, Darvasi E, Chen IM, Cavestro GM, Soucek P, Piredda L, Vodicka P, Gazouli M, Arcidiacono PG, Canzian F, Campa D, Capurso G.
    Sci Rep; 2021 Apr 07; 11(1):7570. PubMed ID: 33828170
    [Abstract] [Full Text] [Related]

  • 5. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.
    Ann Surg; 2022 Jan 01; 275(1):e229-e237. PubMed ID: 32398486
    [Abstract] [Full Text] [Related]

  • 6. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
    Daamen LA, van Goor IWJM, Groot VP, Andel PCM, Brosens LAA, Busch OR, Cirkel GA, Mohammad NH, Heerkens HD, de Hingh IHJT, Hoogwater F, van Laarhoven HWM, Los M, Meijer GJ, de Meijer VE, Pande R, Roberts KJ, Stoker J, Stommel MWJ, van Tienhoven G, Verdonk RC, Verkooijen HM, Wessels FJ, Wilmink JW, Besselink MG, van Santvoort HC, Intven MPW, Molenaar IQ, Dutch Pancreatic Cancer Group.
    Trials; 2024 Jun 20; 25(1):401. PubMed ID: 38902836
    [Abstract] [Full Text] [Related]

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 8. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK.
    J Clin Oncol; 2018 Oct 01; 36(28):2887-2894. PubMed ID: 30106639
    [Abstract] [Full Text] [Related]

  • 9. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec 01; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 10. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A, Procházka V, Hlavsa J, Kiss I, Srovnal J, Kala Z, Slabý O.
    Klin Onkol; 2019 Dec 01; 32(Suppl 1):174-176. PubMed ID: 31064193
    [Abstract] [Full Text] [Related]

  • 11. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
    Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabières C.
    BMC Cancer; 2024 Jun 10; 24(1):709. PubMed ID: 38853244
    [Abstract] [Full Text] [Related]

  • 12. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A.
    Gastroenterology; 2020 Aug 10; 159(2):562-574. PubMed ID: 32376411
    [Abstract] [Full Text] [Related]

  • 13. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.
    Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D.
    Oncologist; 2018 May 10; 23(5):566-572. PubMed ID: 29371474
    [Abstract] [Full Text] [Related]

  • 14. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A.
    Eur J Surg Oncol; 2019 Feb 10; 45(2):218-224. PubMed ID: 30348604
    [Abstract] [Full Text] [Related]

  • 15. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A.
    Clin Cancer Res; 2020 Jul 15; 26(14):3641-3648. PubMed ID: 32234757
    [Abstract] [Full Text] [Related]

  • 16. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 17. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y, Holmes MV, Chen Z, Kartsonaki C.
    J Gastroenterol Hepatol; 2019 Feb 01; 34(2):330-345. PubMed ID: 30550622
    [Abstract] [Full Text] [Related]

  • 18. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, Qian L, Zhao J, Zong H, Kang B, Zou WB, Chen K, He X, Meng Z, Chen Z, Huang S, Wang P.
    Gut; 2020 Mar 01; 69(3):540-550. PubMed ID: 31562239
    [Abstract] [Full Text] [Related]

  • 19. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G.
    PLoS One; 2010 May 14; 5(5):e10630. PubMed ID: 20498843
    [Abstract] [Full Text] [Related]

  • 20. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma.
    Liu DSK, Puik JR, Patel BY, Venø MT, Vahabi M, Prado MM, Webber JP, Rees E, Upton FM, Bennett K, Blaker C, Immordino B, Comandatore A, Morelli L, Sivakumar S, Swijnenburg RJ, Besselink MG, Jiao LR, Kazemier G, Giovannetti E, Krell J, Frampton AE.
    J Exp Clin Cancer Res; 2024 Jul 08; 43(1):189. PubMed ID: 38978141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.